Physician profile
Daniel Brewer
NPI 1013975168
$843.57
in general payments reported to CMS, 2019-2025
15 companies · $52.61 in 2025
The $52.61 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $43.40 · 2022: $79.52 · 2023: $145 · 2024: $185 · 2025: $52.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $187.59 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.84 | 2019-2025 | Lifevest |
| Mallinckrodt Hospital Products INC. | $92.98 | 2022-2024 | Terlivaz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.68 | 2019-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $66.69 | 2019-2022 | |
| Abbvie INC. | $60.18 | 2024-2025 | |
| Portola Pharmaceuticals, LLC | $45.45 | 2019 | |
| Gilead Sciences, INC. | $39.58 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $34.14 | 2019 | |
| Melinta Therapeutics, LLC | $33.85 | 2019 | |
| Vifor Pharma, INC. | $24.76 | 2019 | |
| Daxor Corporation | $20.54 | 2024 | Bva-100 |
| Novartis Pharmaceuticals Corporation | $20.27 | 2019 | |
| Mallinckrodt Enterprises LLC | $19.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Brewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.